Powered by

Tonix to present data on breakthrough therapy designated PTSD at Oppenheimer's Conference

Mar 15, 2017 - Marketline Newswire

Tonix Pharmaceuticals Holding Corp. has announced that it will present data on TNX-102 SL, a drug in Phase III development, recently granted breakthrough therapy designation by the FDA, at Oppenheimer's 27th Annual Healthcare Conference, being held March 21, 2017 to March 22, 2017 in New York.

Seth Lederman, M.D., president and CEO of Tonix, will provide a corporate update and an overview of Tonix's posttraumatic stress disorder (PTSD) clinical program.TNX-102 SL was recently granted B...